On Aug. 25, 2025, C2N Diagnostics (C2N) announced lower age limit addresses increasing calls from clinicians seeking access to the PrecivityAD2™ test for patients with earlier onset of cognitive symptoms; test provides potential to inform earlier intervention.

Clinicians worried about early-onset Alzheimer’s disease in patients with cognitive concerns between the ages of 50 and 55 years can now prescribe the PrecivityAD2™ blood test to aid in the diagnosis of the neurological disorder for that expanded population. The test helps healthcare professionals in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer’s disease, and helps inform medical management and treatment decisions.

C2N Diagnostics introduced the PrecivityAD2 blood tests two years ago for patients 60 years and older. C2N has now completed additional validation to lower the age limit to 50 and older (meaning those born in 1975 and before).

 Alzheimer’s Disease International reports that 75% all dementia cases go undiagnosed across the globe, with the figure rising to 90% in developing countries. C2N believes the expansion of the age range for the PrecivityAD2 test can play a role in reducing these high numbers.  

C2N assays have been used in over 150 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease.